0001739074-20-000013.txt : 20201020
0001739074-20-000013.hdr.sgml : 20201020
20201020124440
ACCESSION NUMBER: 0001739074-20-000013
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20201020
DATE AS OF CHANGE: 20201020
EFFECTIVENESS DATE: 20201020
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nuvation Bio Inc.
CENTRAL INDEX KEY: 0001829093
IRS NUMBER: 833460372
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-378335
FILM NUMBER: 201247843
BUSINESS ADDRESS:
STREET 1: 1500 BROADWAY
STREET 2: SUITE 1401
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 650-245-3818
MAIL ADDRESS:
STREET 1: 1500 BROADWAY
STREET 2: SUITE 1401
CITY: NEW YORK
STATE: NY
ZIP: 10036
D
1
primary_doc.xml
X0708
D
LIVE
0001829093
Nuvation Bio Inc.
1500 BROADWAY
SUITE 1401
NEW YORK
NY
NEW YORK
10036
650-245-3818
DELAWARE
RePharmation Inc.
None
Corporation
true
2018
David
Hung, M.D.
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Executive Officer
Director
Kim
Blickenstaff
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Director
Michelle
Doig
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Director
Robert
Bazemore
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Director
Claudio
Nessi
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Director
W.
Anthony
Vernon
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Director
Daniel
Welch
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Director
Kathryn
E.
Falberg
1500 Broadway
Suite 1401
New York
NY
NEW YORK
10036
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2019-06-17
true
true
false
0
275348195
275348195
0
Includes $15,000,000 in value of cancelled convertible instruments.
false
57
0
0
0
false
Nuvation Bio Inc.
/s/ David Hung, M.D.
David Hung, M.D.
Chief Executive Officer
2020-10-20